Pancreatic Cancer Research

ResearcherNara Medical UniversityActive in the last 2 years

Toshihiro Tanaka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3756-5278; OpenAlex author ID A5101682111. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 13

  1. An axon guidance-related microRNA panel identifies perivascular plexus local recurrence following curative surgery in patients with pancreatic cancer. Co-author DOI 10.1007/s00535-025-02260-w↗
  2. Risk Factors for Late-Onset Gastrointestinal Hemorrhage After Pancreatoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1007/s00268-018-4791-7↗
  3. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Ca… Co-author DOI 10.1007/s00268-018-4820-6↗
  4. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.05.461↗
  5. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-018-1709-7↗
  6. Adjuvant Hepatic Arterial Infusion Chemotherapy After Resection for Pancreatic Cancer Using Coaxial Catheter-Port System Compared with Conventional System. First author DOI 10.1007/s00270-016-1292-7↗
  7. Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2015.10.034↗
  8. Importance of resectability status in neoadjuvant treatment for pancreatic cancer. Co-author DOI 10.1002/jhbp.258↗
  9. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1007/s00423-015-1304-0↗
  10. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. Co-author DOI 10.1007/s00534-012-0532-8↗
  11. Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabin… Co-author DOI 10.2214/ajr.11.8008↗
  12. Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. First author DOI 10.1007/s00534-010-0336-7↗
  13. Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer. Co-author PMID 22110218↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Sho · 13 shared papers, 2011–2025 · strength 0.88
  2. Minako Nagai · 8 shared papers, 2015–2025 · strength 0.72
  3. Kimihiko Kichikawa · 11 shared papers, 2011–2019 · strength 0.62
  4. Satoshi Nishiwada · 6 shared papers, 2015–2025 · strength 0.58
  5. Kota Nakamura · 5 shared papers, 2018–2025 · strength 0.57
  6. Takahiro Akahori · 9 shared papers, 2011–2019 · strength 0.54
  7. Hideyuki Nishiofuku · 9 shared papers, 2011–2019 · strength 0.45
  8. Kenji Nakagawa · 4 shared papers, 2018–2019 · strength 0.34
  9. Naoya Ikeda · 4 shared papers, 2018–2019 · strength 0.34
  10. Chiho Ohbayashi · 5 shared papers, 2015–2019 · strength 0.31
  11. Yoshiyuki Nakajima · 8 shared papers, 2011–2016 · strength 0.31
  12. Satoshi Yasuda · 2 shared papers, 2013–2025 · strength 0.26
  13. Yuichiro Kohara · 1 shared paper, 2025 · strength 0.23
  14. Taichi Terai · 1 shared paper, 2025 · strength 0.23
  15. Shoichi Kinoshita · 4 shared papers, 2013–2016 · strength 0.18
  16. Tadataka Takagi · 1 shared paper, 2019 · strength 0.09
  17. Hitoshi Yoshiji · 1 shared paper, 2019 · strength 0.08
  18. Ichiro Yamato · 2 shared papers, 2011–2013 · strength 0.05
  19. Aya Hashimoto · 1 shared paper, 2016 · strength 0.05
  20. Kimihiko Kichikaiwa · 1 shared paper, 2012 · strength 0.03
  21. Chihiro Kawaguchi · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.